Crinetics Pharmaceuticals (CRNX): Billionaire Tom Steyer Likes This Pharma Stock

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) archetypal appeared successful the 13F portfolio of Farallon Capital successful the 3rd 4th of 2018. Back then, this presumption comprised implicit 141,000 shares. By aboriginal 2019, however, this involvement had been sold disconnected completely. A caller presumption successful the banal was past opened successful the 3rd 4th of 2023. This was besides sold disconnected wrong months. The latest involvement was disclosed successful filings for the 2nd 4th of 2024. This comprised conscionable nether 500,000 shares. The money has steadily added to this presumption since then. Filings for the 4th fourth of 2025 amusement that the money owned conscionable nether 7 cardinal shares successful the firm, up 20% compared to filings for the erstwhile quarter.

The superior catalyst for Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is the planetary motorboat of PALSONIFY, the archetypal once-daily oral attraction for acromegaly. Earlier this month, Crinetics received European Commission approval, pursuing its earlier US FDA clearance. This makes it the lone oral alternate to the painful, monthly somatostatin analogue injections that presently predominate the market. Hedge funds are betting connected accelerated adoption. Early information shows a 5% adoption complaint wrong conscionable months of launch, with analysts projecting 2026 revenues to deed $62 million, importantly higher than archetypal statement estimates.

While we admit the imaginable of CRNX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 14 Best Defensive Stocks to Invest In Now and 14 Best Low Risk High Growth Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey connected Google News.